biotech · Hematological or solid tumor malignancies or autoimmune diseases · Intracerebral Haemorrhage · IPSC
Century Therapeutics
Century Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Philadelphia, USA
- Founded
- 2018
- Employees
- 104
- Programs
- 10
- Drugs
- 9
- Patents
- 39
Century Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Century Therapeutics.
Century Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CNTY-101
Century Therapeutics
R/R CD19-Positive B-Cell Malignancies
1 trial -
CNTY-101
Century Therapeutics
Systemic Lupus Erythematosus
1 trial -
CNTY-101-151-01
Century Therapeutics
systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]
1 trial -
CNTY-LTFU-01
Century Therapeutics
Hematological or solid tumor malignancies or autoimmune diseases
1 trial -
Nicotine gum (C)
Century Therapeutics
Tobacco Use
2 trials
Frequently asked questions
How many clinical projects does Century Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.